The delayed approval and price setting of Novartis Pharma’s Zolgensma (onasemnogene abeparvovec), a gene therapy for spinal muscular atrophy (SMA) listed in May, has raised questions about how the sakigake designation system should be operated. Despite being designated for the…
HOME > ORGANIZATION
ORGANIZATION
- JPMA to Vet Impact of Drug Pricing Reform, Make Proposals for R&D Tax Break System: FY2020 Project Plan
April 8, 2020
- Tohoku Medical Megabank, JPMA Initiate Joint Research on Preventive and Preemptive Health
April 2, 2020
- Keidanren Calls for Support in Drug, Vaccine Development: Emergency Proposal
March 31, 2020
- Japan Pharma Industry Presses for 100 Billion Yen Emergency Package over Coronavirus, Stable Supplies
March 31, 2020
- FPMAJ Launches Survey to Gauge COVID-19 Impact on Drug Supplies
March 27, 2020
- Generic Use Rate at 77.1% in October-December 2019: JGA
March 27, 2020
- Japan Pharma Lobbies Hammer Out One-Year Term Extensions for Their Leaders
March 24, 2020
- JPMA Chief Fires Back at Health Policy Advisor’s “Plenty of Financial Strength” Comment
March 23, 2020
- JPMA Members Increasing Drug Stockpiles to Deal with COVID-19, Need Govt Support: Chief
March 23, 2020
- Japanese Drug Firms Providing APIs for NIID Screening for COVID-19: JPMA Survey
March 19, 2020
- Teshirogi, Nakayama to Lead Japan Pharma Lobbies for 1 More Year; Ex-MHLW Official Shiraishi to Join JPMA
March 16, 2020
- India’s API Export Curb Could Eventually Affect At Least 2 Firms, FPMAJ Finds
March 10, 2020
- Japan Infectious Diseases Society Shares Latest Knowledge on Antivirals against COVID-19
February 28, 2020
- Japan Pharma Lobbies Likely to Retain Chiefs as Off-Year Re-Pricing Debate Looms
February 21, 2020
- PhRMA Japan Continues Push Against Off-Year Re-Pricing for Innovative Drugs, HTA Use in Reimbursement Decisions in 2020
February 20, 2020
- FPMAJ Creates Scheme to Deal with Drug Supply Disruptions; Companies to Set Up “Supply Adjustment Teams”
February 12, 2020
- Drug Formularies Won’t Invade Doctors’ Rights to Prescribe: Payer Rep
February 10, 2020
- RAD-AR Council Accelerating Initiative to Prepare Medication Guides in English toward Tokyo 2020 Olympic and Paralympic Games
February 6, 2020
- Insurance Association to Send Copayment Differences Notification to 15 Year-Old and Over as well to Achieve 80% Generic Target
February 6, 2020
- Japan Red Cross Set to Push Formularies at All Group Hospitals, Despite Medical Fee Plan Dropped
February 5, 2020
ページ
When Jiho surveyed drug makers on the non-sales criteria they use to evaluate reps’ performance, it received a variety of…
Nearly a year after the introduction of the Ministry of Health, Labor and Welfare’s (MHLW) drug promotion guidelines in April…
Advancements in modified oligonucleotide technologies has been the key driver behind a spate of approvals in the oligonucleotide therapeutics space…
Japan’s key reimbursement policy panel on December 20 approved an outline of its FY2020 drug pricing reform next April, with…
The Ministry of Health, Labor and Welfare (MHLW) on November 27 added to the NHI price list Japan’s first biosimilars of Avastin (bevacizumab), Nesp (darbepoetin alfa), and Forteo (teriparatide). The NHI prices of first biosimilars are set at 70% of…
A total of 51 new drugs joined the NHI price list in 2019, which are expected to generate combined peak sales of 373 billion yen, according to Jiho’s tally of data submitted to a key reimbursement policy panel. The relatively…
Some seven years in the making, Japan’s Ministry of Health, Labor and Welfare (MHLW) finally rolled out a cost-effectiveness assessment…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…
In a change striking to the very core of the traditional Japanese salaryman, “We are seeing the coronavirus ushering in a new way of working… and I think it’s about time,” says Ivan Tselichtchev, Professor of Economics at the Niigata…